$GSK Zejula as a first option to keep advanced ovarian cancer at bay in women who have responded to chemotherapy

Zejula will compete with rival PARP inhibitors, which include AstraZeneca $AZN and Merck &amp; Co's $MRK Lynparza and Clovis Oncology's $CLVS Rubraca.